drugset / Trial / NCT01660763

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

NCT01660763

Phase 3 Completed 419 enrolled Talphera, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of the Sufentanil NanoTab PCA System/15 mcg to the Placebo Sufentanil NanoTab PCA System for the management of acute moderate to severe post-operative pain after total unilateral knee or total unilateral hip replacement surgery.

Timeline

Start
2012-08
Primary completion
2013-04
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 15 ug Other

Indications

No indication recorded.